Safety and effectiveness of LORLAtinib as a FIRST-line treatment in an ALK-positive Advanced Non-Small Cell Lung Cancer Spanish population. (LORLA-FIRST).

First published 04/06/2025

Last updated 04/06/2025

EU PAS number:

EUPAS1000000406

Study

Planned

Documents

Study protocol

Initial protocol

B7461054_Non-Interventional Study Protocol_V1.0_10APR2025_Redacted.pdf

English (15.13 MB - PDF) View document

Study results

Study report

Other information

Secondary tabs